AIMS: We hypothesized that subjects with a normal body mass index (BMI), but high body fat (BF) content [normal weight obesity (NWO)], have a higher prevalence of cardiometabolic dysregulation and are at higher risk for cardiovascular (CV) mortality. METHODS AND RESULTS: We analysed 6171 subjects >20 years of age from the Third National Health and Nutrition Examination Survey (NHANES III) and the NHANES III mortality study, whose BMI was within the normal range (18.5-24.9 kg/m(2)), and who underwent a complete evaluation that included body composition assessment, blood measurements, and assessment of CV risk factors. Survival information was available for >99% of the subjects after a median follow-up of 8.8 years. We divided our sample using sex-specific tertiles of BF%. The highest tertile of BF (>23.1% in men and >33.3% in women) was labelled as NWO. When compared with the low BF group, the prevalence of metabolic syndrome in subjects with NWO was four-fold higher (16.6 vs. 4.8%, P < 0.0001). Subjects with NWO also had higher prevalence of dyslipidaemia, hypertension (men), and CV disease (women). After adjustment, women with NWO showed a significant 2.2-fold increased risk for CV mortality (HR = 2.2; 95% CI, 1.03-4.67) in comparison to the low BF group. CONCLUSION: Normal weight obesity, defined as the combination of normal BMI and high BF content, is associated with a high prevalence of cardiometabolic dysregulation, metabolic syndrome, and CV risk factors. In women, NWO is independently associated with increased risk for CV mortality.
AIMS: We hypothesized that subjects with a normal body mass index (BMI), but high body fat (BF) content [normal weight obesity (NWO)], have a higher prevalence of cardiometabolic dysregulation and are at higher risk for cardiovascular (CV) mortality. METHODS AND RESULTS: We analysed 6171 subjects >20 years of age from the Third National Health and Nutrition Examination Survey (NHANES III) and the NHANES III mortality study, whose BMI was within the normal range (18.5-24.9 kg/m(2)), and who underwent a complete evaluation that included body composition assessment, blood measurements, and assessment of CV risk factors. Survival information was available for >99% of the subjects after a median follow-up of 8.8 years. We divided our sample using sex-specific tertiles of BF%. The highest tertile of BF (>23.1% in men and >33.3% in women) was labelled as NWO. When compared with the low BF group, the prevalence of metabolic syndrome in subjects with NWO was four-fold higher (16.6 vs. 4.8%, P < 0.0001). Subjects with NWO also had higher prevalence of dyslipidaemia, hypertension (men), and CV disease (women). After adjustment, women with NWO showed a significant 2.2-fold increased risk for CV mortality (HR = 2.2; 95% CI, 1.03-4.67) in comparison to the low BF group. CONCLUSION: Normal weight obesity, defined as the combination of normal BMI and high BF content, is associated with a high prevalence of cardiometabolic dysregulation, metabolic syndrome, and CV risk factors. In women, NWO is independently associated with increased risk for CV mortality.
Authors: Antonino De Lorenzo; Vera Del Gobbo; Maria Grazia Premrov; Mario Bigioni; Fabio Galvano; Laura Di Renzo Journal: Am J Clin Nutr Date: 2007-01 Impact factor: 7.045
Authors: Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Leonelo Bautista; Maria Grazia Franzosi; Patrick Commerford; Chim C Lang; Zvonko Rumboldt; Churchill L Onen; Liu Lisheng; Supachai Tanomsup; Paul Wangai; Fahad Razak; Arya M Sharma; Sonia S Anand Journal: Lancet Date: 2005-11-05 Impact factor: 79.321
Authors: Abel Romero-Corral; Victor M Montori; Virend K Somers; Josef Korinek; Randal J Thomas; Thomas G Allison; Farouk Mookadam; Francisco Lopez-Jimenez Journal: Lancet Date: 2006-08-19 Impact factor: 79.321
Authors: Paul Poirier; Thomas D Giles; George A Bray; Yuling Hong; Judith S Stern; F Xavier Pi-Sunyer; Robert H Eckel Journal: Circulation Date: 2005-12-27 Impact factor: 29.690
Authors: A Romero-Corral; V K Somers; J Sierra-Johnson; R J Thomas; M L Collazo-Clavell; J Korinek; T G Allison; J A Batsis; F H Sert-Kuniyoshi; F Lopez-Jimenez Journal: Int J Obes (Lond) Date: 2008-02-19 Impact factor: 5.095
Authors: Rachel P Wildman; Paul Muntner; Kristi Reynolds; Aileen P McGinn; Swapnil Rajpathak; Judith Wylie-Rosett; MaryFran R Sowers Journal: Arch Intern Med Date: 2008-08-11
Authors: John K Ninomiya; Gilbert L'Italien; Michael H Criqui; Joanna L Whyte; Anthony Gamst; Roland S Chen Journal: Circulation Date: 2003-12-15 Impact factor: 29.690
Authors: Paolo Marzullo; Laura Di Renzo; Gabriella Pugliese; Martina De Siena; Luigi Barrea; Giovanna Muscogiuri; Annamaria Colao; Silvia Savastano Journal: Int J Obes Suppl Date: 2020-07-20
Authors: Yong-Moon Mark Park; Alexandra J White; Hazel B Nichols; Katie M O'Brien; Clarice R Weinberg; Dale P Sandler Journal: Int J Cancer Date: 2017-03-28 Impact factor: 7.396
Authors: Jason M Ng; Alessandra Bertoldo; Davneet S Minhas; Nicole L Helbling; Paul M Coen; Julie C Price; Claudio Cobelli; David E Kelley; Bret H Goodpaster Journal: J Clin Endocrinol Metab Date: 2013-12-20 Impact factor: 5.958
Authors: Carlos M Diaz-Melean; Virend K Somers; Juan Pablo Rodriguez-Escudero; Prachi Singh; Ondrej Sochor; Ernesto Manuel Llano; Francisco Lopez-Jimenez Journal: Curr Atheroscler Rep Date: 2013-11 Impact factor: 5.113